Literature DB >> 12112073

Evolution of the response to levodopa during the first 4 years of therapy.

John G Nutt1, Julie H Carter, Eric S Lea, Gary J Sexton.   

Abstract

The short-duration response, long-duration response, and dyskinetic response to levodopa change during long-term levodopa therapy. How these responses evolve, and which changes contribute to the emergence of motor fluctuations, remain unclear. We studied 18 subjects with Parkinson's disease before they began levodopa therapy and after 6, 12, 24, and 48 months of long-term levodopa therapy. The responses to 2-hour levodopa infusions after overnight and after 3 days of levodopa withdrawal were studied from 6 months onward. The mean magnitude of the short-duration response and the long-duration response measured after overnight without antiparkinsonian medications did not change during the 4 years. However, after 3 days without levodopa, it was apparent that the short-duration-response magnitude was progressively increasing (p < 0.0001) and that the long-duration response was decaying more rapidly (p = 0.0004). The short-duration-response magnitude at 4 years was inversely related to the long-duration-response magnitude (p = 0.022), suggesting that the long-duration response was one determinant of the short-duration-response magnitude. Dyskinesia increased progressively in severity during the study (p = 0.013). The duration of the short-duration response and dyskinesia did not change during the 4 years. Subject reports of motor fluctuations tended to be associated with a large short-duration response (p = 0.054). We suggest that a larger long-duration response, rather than a shortened one, is more important to the development of fluctuations. Improving the baseline or practical-off motor function to reduce the magnitude of the short-duration response may be a strategy to treat fluctuations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112073     DOI: 10.1002/ana.10189

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

2.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

3.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

5.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  Activity enhances dopaminergic long-duration response in Parkinson disease.

Authors:  Un Jung Kang; Peggy Auinger
Journal:  Neurology       Date:  2012-03-28       Impact factor: 9.910

7.  Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Authors:  John G Nutt; Kathy A Chung; Nicholas H G Holford
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

8.  Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.

Authors:  R Hilker; A T Portman; J Voges; M J Staal; L Burghaus; T van Laar; A Koulousakis; R P Maguire; J Pruim; B M de Jong; K Herholz; V Sturm; W-D Heiss; K L Leenders
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

Review 9.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

10.  Dissociable effects of dopamine on learning and performance within sensorimotor striatum.

Authors:  Daniel K Leventhal; Colin Stoetzner; Rohit Abraham; Jeff Pettibone; Kayla DeMarco; Joshua D Berke
Journal:  Basal Ganglia       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.